Varex Imaging Stock News

Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.

The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.

Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.

According to the new market research report "X-Ray Detectors Market by Technology (Flat Panel, CCD, CR Detector), Application (Medical, Orthopedic, Industrial, Veterinary, Security), FPD (Type (Gadox, CSL, Direct), Portability (Fix, Portable), Platform (Digital, Retrofit)) - Global Forecast to 2026", published

Equities research analysts expect that Varex Imaging Co. (NASDAQ:VREX) will report sales of $210.05 million for the current quarter, Zacks reports. Two analysts have made estimates for Varex Imagings earnings. The highest sales estimate is $210.10 million and the lowest is $210.00 million. Varex Imaging posted sales of $177.10 million in the same quarter last []

Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.

Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.